Eli Lilly's Zepbound Combined With Amylin Drug Led To 23% Weight Loss In Mid-Stage Trial
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
Eli Lilly
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.”
MarketWatch — Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.“An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.”
stat news — STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial